Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Lying down for science: how 10 days of bed rest and fasting could help astronauts

NCT ID NCT07499167

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 10, 2026 · Updated 1 time

Summary

This study puts 10 healthy men on 10 days of strict bed rest with their heads tilted down, combined with a controlled low-calorie diet, to mimic the effects of space travel. Researchers will measure changes in muscle, heart, blood, brain, and metabolism. The goal is to understand how the body responds to these extreme conditions, which could inform future astronaut health protocols.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
head-down bed rest and caloric restriction
What this could lead to
If successful, this could help scientists understand how to protect astronauts' health during long space missions, especially regarding muscle loss and metabolism.
What could go wrong
This is a very small pilot study with only 10 healthy men, so results may not apply to women or other populations. It is exploratory, not designed to prove any treatment works.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 10 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2026

Expected to finish

Sep 2027

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

20 to 40 years

Sex

Male participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Healthy male volunteers (see below the description of medical tests and laboratory analysis performed at the selection visit) * Certified as healthy by a comprehensive clinical assessment (detailed medical history and complete physical examination): in particular, free from any known chronic disease or any acute mood or eating disorder, infectious disease or cardiovascular, metabolic, neurological, ENT (especially orthostatic hypotension and vestibular disorders), orthopedic or musculoskeletal disorders. * 20 to 40 years old * 165 to 185 cm * Body Mass Index between 20 and 26 kg.m-2 * Stable body weight in the past 3 months (less than 4% change) * Fat Mass Index (FMI), defined as (bodyfat weigh in kg)/(height in m)2: between 3 and 6 kg.m-2, measured by whole-body DEXA * Triglyceride level under 1.7 mmol.L-1 * Normal bone mass density at left hip and lumbar spine: T-score\>-1.5, measured by DEXA * VO2peak/VO2max between 35 and 55 mL.min-1.kg-1 * Non-smokers * No alcohol or drug dependence, no medical treatment on a regular basis * Affiliated to a Social Security system and, for non-French resident, holding a European Health Insurance Card (EHIC) or a Global Health Insurance Card (GHIC). * Free of any engagement during the study * Who agreed to take part in the study and signed the informed consent Exclusion Criteria: * Any history or presence of clinically relevant chronic disease; any acute infectious disease. Particularly (but not limited to): * Symptomatic orthostatic hypotension whatever the decrease in blood pressure, or asymptomatic postural hypotension defined by a decrease in SBP equal to or greater than 20 mmHg within 3 minutes when changing from the supine to the standing position * Personal or family history of thrombosis, genetic mutation for factor V or prothrombin gene * Cardiac arrhythmia * Hypertension * Auto-immune diseases or Raynaud's syndrome * History or symptoms of sleep apnea * Chronic back pains, * Vertebral fracture, scoliosis, or herniated disc, * Color-blindness, * Self-reported hearing problems or binocular visual acuity under 6/10 after correction * Vestibular disorders * Drug addiction * History of migraines, * History of hiatus hernia or gastro-esophageal reflux, * History of thyroid dysfunction or diabetes * History of head trauma, * History of neurological diseases (e.g. epilepsy) * History of genetic muscle and bone diseases of any kind * Significant history of allergies * Significant abnormality in blood tests * Positive serology for hepatitis A, hepatitis B, hepatitis C or AIDS (HIV) virus * Mood and Eating disorder (current or past), screened with the Hospital Anxiety Depression Scale (HADS), SCOFF (Sick, Control, One, Fat, Food) and the Eating Disorder Examination Questionnaire (EDE-Q) * Antibiotics exposure 2 months prior to the study * Major lifestyle changes (e.g. significant weight/body changes, diet or exercises regimen) 6 months prior to the study * Specific diet (e.g vegan, carnivore, intermittent fasting, dietary supplements consumption) * History of hypocaloric diet, judged as significant by the investigator * Subject who, in the judgment of the investigator, is likely to be non-compliant during the study, or unable to cooperate because of a language problem or poor mental development, * Subject in the exclusion period of another clinical research, * Subject who received 6000 Euros or more within 12 months for being a research subject, * Poor tolerance to blood sampling, * Subject who cannot be contacted in case of emergency, * Contraindications for MRI: claustrophobia, presence of osteosynthesis material or metal implants, * Blood donation of more than 7 ml/kg in the 8 weeks prior to the start of the study, * Vulnerable people according to law "Code de la Santé Publique" (L1121-5 to L1121-8): * Pregnant or nursing women (urine pregnancy test for women of childbearing potential) * People deprived of their liberty by an administrative or judicial decision * People under involuntary psychiatric care * People admitted in a health or social establishment for purposes other than research * Minors * Adults subject to legal protection (subject under guardianship or trusteeship) or unable to express their consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Caloric restriction are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Medes - Imps

    Toulouse, Medes-imps, 31400, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.